Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?

Abbott Laboratories' Diabetes Care division, driven by its FreeStyle Libre continuous glucose monitoring (CGM) platform, reported robust Q2 2025 sales of $1.90 billion, an organic increase of 19.6%, fueled by strong demand and recent FDA approvals for over-the-counter CGM systems Lingo and Libre Rio. This positions Abbott favorably within the rapidly expanding global diabetes care market, projected to reach $99.81 billion by 2035, with further growth anticipated from its upcoming dual-analyte CGM launch. Despite its shares outperforming the industry year-to-date, ABT currently trades at a forward 12-month Price-to-Sales of 4.84x, a discount to the industry average of 5.63x.

Analysis

Abbott Laboratories' Diabetes Care division continues to be a primary growth engine, underscored by a 19.6% organic increase in sales to $1.90 billion in Q2 2025, with U.S. sales of its flagship FreeStyle Libre platform surging nearly 26%. This performance solidifies Abbott's leadership in a continuous glucose monitoring (CGM) market projected to expand at a 9.6% CAGR through 2035. The company's growth strategy is multifaceted, focusing on expanding its user base across all patient types and innovating its product portfolio. Recent FDA approvals for over-the-counter CGM systems, Lingo and Libre Rio, represent a significant strategic expansion into the consumer wellness space, while the planned launch of a dual-analyte sensor with ketone monitoring is positioned as a key differentiator to capture a larger share of the intensive insulin user market. Despite its stock's 19.7% year-to-date gain, which outpaces the industry's 7.9% growth, Abbott trades at a forward price-to-sales multiple of 4.84x, a notable discount to the industry average of 5.63x. This favorable valuation is tempered slightly by a minor 0.2% downward revision in projected 2025 earnings per share over the past 30 days.

Key Decisions for Investors

• Given the strong top-line growth in Diabetes Care, a robust product pipeline, and a discounted valuation relative to the industry, investors could consider the stock favorably positioned for long-term growth.
• Monitor the competitive landscape closely, particularly the market adoption of DexCom's OTC product, Stelo, as it directly competes with Abbott's new consumer-focused strategy and could influence future market share.
• The upcoming launches of the Lingo, Libre Rio, and the dual-analyte ketone sensor are critical catalysts; their successful commercialization could validate the growth narrative and potentially lead to a re-rating of the stock.